Boston Scientific Corporation $BSX Position Trimmed by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. decreased its holdings in Boston Scientific Corporation (NYSE:BSX) by 93.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,716 shares of the medical equipment provider’s stock after selling 23,573 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Boston Scientific were worth $168,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in BSX. Steph & Co. acquired a new position in Boston Scientific in the 3rd quarter valued at approximately $25,000. 1248 Management LLC purchased a new position in shares of Boston Scientific during the 1st quarter valued at $26,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the second quarter worth $26,000. Sound Income Strategies LLC increased its stake in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. Finally, Kilter Group LLC purchased a new stake in shares of Boston Scientific during the second quarter worth $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 143,095 shares of company stock worth $14,228,950 in the last quarter. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Up 0.8%

BSX opened at $92.93 on Wednesday. The firm has a market cap of $137.76 billion, a P/E ratio of 49.70, a price-to-earnings-growth ratio of 1.86 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The business has a 50 day moving average price of $98.70 and a 200 day moving average price of $101.42. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter last year, the company posted $0.63 earnings per share. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent research reports. Truist Financial boosted their target price on Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. UBS Group boosted their price target on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Thursday, October 23rd. Finally, Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $125.40.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.